Brandes et al11 | 103 | Enhancement increase for earlier progression than Macdonald criteria | 4 Weeks | 50/103 | 32/50 | 32/103 |
J Clin Oncol 200820 | | | | (48.5%) | (64%) | (31%) |
Taal et al | 85 | Macdonald Criteria | 4 Weeks | 36/85 | 15/31a | 15/85 |
Cancer 200810 | | | | (42%) | (48%) | (17.6%) |
Clarke et al | 80 | Increased contrast enhancement | Not specified | 33/80 | 8/25a | 8/80 |
(abstract) J Clin Oncol 200817 | | | | (41%) | (32%) | (10%) |
Gerstner et al | 45 | Macdonald Criteria | 17–28 Days | 24/45 | 13/24 | 13/45 |
J Neurooncol 200918 | | | | (53%) | (54%) | (29%) |
Jefferies et al | 15 | Not specified | 6 Months | 9/15 | 3/9 | 3/15 |
abstract Clin Oncol 200719 | | | | (60%) | (33%) | (20%) |
Chaski et al | 54 | Increased contrast enhancement | 6 Months | 25/54 | 3/25 | 3/54 |
Surg Neurol 200914 | | | | (46%) | (12%) | (5.5%) |
Sanghera et al | 104 | RECIST | 8 Weeks | 27/104 | 7/22a | 7/104 |
Can J Neurol Sci 201016 | | | | (26%) | (32%) | (7%) |
Mangla et al | 36 | Macdonald Criteria | 4 Weeks | 19/36 | 7/19 | 7/36 |
Radiology 201015 | | | | (53%) | (37%) | (20%) |